Deal of the Day — limited-time pharmacy picks!
Cytarzer 500mg Injection

Cytarzer 500mg Injection

Prescription requiredRx Required

Salt Composition: Cytarabine

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

1 injection

About The Product

Blood  Cancer

Description

Cytarzer 500mg Injection is an anticancer injection prescribed by the doctor to treat various types of blood cancers including acute myeloid leukemia (AML), acute non-lymphoblastic leukemias, and acute lymphoblastic leukemia (ALL) etc. It is also given to treat blast crises in chronic myeloid leukemia and erythroleukemia.

It also helps in the management of Management of meningeal leukemia and meningeal neoplasms via intrathecal administration. Cytarabine is the active ingredient of this medication.

It is often combined with other drugs like daunorubicin for remission induction in adults and pediatric patients.

Common Side Effects

  • Like any other chemical based medication, Cytarzer 500mg Injection also has multiple side effects that can ranges from common to serious.
  • Immediately contact your doctor if symptoms persist for longer period of time.
  • Seek immediate Medical Attention in case of serious side effects. ● Infections ● Fever ● Cytarabine syndrome ● Nausea ● Vomiting ● Diarrhea ● Abdominal pain ● Loss of appetite ● Mouth sores ● Hair loss ● Skin Reactions ● Fatigue ● Headaches ● Dizziness ● Eye Problems ● Bone Pain ● Fast heartbeat ● Injection site reactions

Dosage And Administration

  • Cytarzer 500mg Injection is administered intravenously.
  • It can also be administered subcutaneously or intrathecally either alone or with other cancer treatment therapies, depending on the cancer's type and stage.
  • Patients should not self-administer; it must be injected by a doctor or trained nurse.
  • Consult a doctor for precise dosage and timing.

Mechanism Of Action

Cytarzer Injection contains 500mg of Cytarabine that works as an antimetabolite chemotherapy.Cytarabine inhibits DNA polymerase, blocking DNA chain elongation, synthesis, and repair during the S-phase of the cell cycle. It also incorporates into DNA and RNA, disrupting replication and causing chain termination.

As a result, cancer cells are not able to multiply and eventually reduce in number.

Safety Advice

Alcohol
It is advisable not to consume alcohol while taking Cytarzer 500mg Injection as it can worsen the side effects. It is advised to consult your doctor for further information.
Driving
It is advisable not to drive, as you may feel dizzy after taking Cytarzer 500mg.
Pregnancy
Cytarzer Injection is considered unsafe during pregnancy due to foetal harm. Please consult your doctor in such condition.
Breast Feeding
Breast Feeding is not advisable during the Cytarzer 500mg Injection treatment Course. Consult your Doctor for more information.
Kidney
Share your medical history with your doctor in case of kidney disease before taking Cytarzer 500mg Injection.
Liver
Notify your doctor about any liver disease or infection before starting Cytarzer Injection course.

Faqs

Cytarzer 500mg Injection is an antimetabolite therapy based injection.

It is used to treat various types of blood cancers including acute myeloid leukemia (AML), acute non-lymphoblastic leukemias, and acute lymphoblastic leukemia (ALL) etc

References

• Liu, J. C., Wang, D., Callen, E., Chen, C., Noriega, S., Shang, Y., ... & Nussenzweig, A.

(2025). Mechanism of cytarabine-induced neurotoxicity.

Nature, 1-10. • Poodeh, A. M., Sarab, G.

A., Ravari, M. P., Najafzadeh, M., Safarpour, H., Zarban, A., ... & Sajjadi, S.

M. (2025).

Metformin and chloroquine enhanced the efficacy of cytarabine in acute lymphoblastic leukemia cell lines: a drug repositioning approach. Scientific Reports, 15(1), 16510. • Karunarathna, I.

(2025). Cytarabine in Hematologic Malignancies: Mechanisms, Clinical Applications, Toxicities, and Multidisciplinary Considerations. • Alzahrani, A.

M., Alnuhait, M. A., & Alqahtani, T.

(2025). The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review.

Cancer Reports, 8(5), e70199.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026